Market moves signaled investor appetite for AI and immune‑focused biotechs. BioCentury reported Insilico’s shares posted strong gains after its Hong Kong listing, while Psithera (formerly Psivant) completed a $47.5 million Series A after spinning out from Roivant and reorienting around immune and inflammatory small‑molecule programs. Insilico’s rally underscores continued investor interest in AI‑driven discovery platforms, and Psithera’s financing highlights appetite for mid‑stage immunology plays emerging from larger venture portfolios. Both developments suggest that capital remains accessible for differentiated computational and immune‑drug platforms despite broader market volatility.